Susquehanna International Group, LLP Corcept Therapeutics Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$29.51 - $46.26 $6.44 Million - $10.1 Million	-218,200 Reduced 51.46%	205,800 $9.52 Million
Q2 2024 Aug 15, 2024	BUY	$22.21 - $34.48 $299,835 - $465,479	13,500 Added 3.29%	424,000 $13.8 Million
Q1 2024 May 07, 2024	BUY	$21.1 - $27.46 $6.11 Million - $7.95 Million	289,600 Added 239.54%	410,500 $10.3 Million
Q4 2023 Feb 14, 2024	BUY	$24.82 - $32.88 $1.63 Million - $2.16 Million	65,700 Added 119.02%	120,900 $3.93 Million
Q3 2023 Nov 14, 2023	BUY	$21.97 - $33.8 $962,286 - $1.48 Million	43,800 Added 384.21%	55,200 $1.5 Million
Q2 2023 Aug 11, 2023	SELL	$21.44 - $25.15 $947,648 - $1.11 Million	-44,200 Reduced 79.5%	11,400 $253,000
Q1 2023 May 16, 2023	SELL	$19.2 - $24.47 $1.11 Million - $1.41 Million	-57,800 Reduced 50.97%	55,600 $1.2 Million
Q4 2022 Feb 14, 2023	BUY	$19.95 - $29.96 $1.27 Million - $1.91 Million	63,800 Added 128.63%	113,400 $2.3 Million
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $321,100 - $378,560	13,000 Added 35.52%	49,600 $1.27 Million

346

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.51B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.